KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31

Pasithea Therapeutics Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.41−0.01 (-1.83%)

Close on Oct 19, 2026

Market cap: $13.23M
P/E (TTM): –
Dividend yield: –

Pasithea Therapeutics Corp. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31
Stock-Based Compensation	0.61	0.34	0.30	0.33	0.40	0.47	0.77	0.67	0.65	0.71	0.59	0.63	0.51	0.88	0.84	0.84	0.87	–	0.47
Change in Accounts Payable	0.26	0.16	0.01	0.70	0.19	-1.11	-1.43	-1.23	-0.52	0.99	1.07	0.67	1.12	0.68	0.75	0.38	0.05	0.24	0.44
Operating Cash Flow	-18	-17	-15	-12	-12	-13	-14	-15	-15	-14	-13	-13	-14	-13	-12	-10	-6.38	-4.94	-3.17
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	-0.03	-0.13	-0.16	-0.16	-0.11	-0.03	–	–	-0.02
Acquisitions	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-2.19	–	–	–	–
Sale of Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	0.11	–	–	–	–	–	–	–	–
Investing Cash Flow	–	–	–	–	–	–	–	–	–	–	0.08	-2.32	-2.40	-2.35	-2.30	0.03	–	–	-0.02
Share Repurchases	–	–	–	–	–	–	–	–	–	–	-3.73	–	–	–	–	–	–	–	–
Stock Issued	–	–	2.08	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.21
Financing Cash Flow	56	62	64	7.07	–	–	4.52	–	–	–	-3.73	–	–	–	–	–	–	–	56
Foreign Exchange Rate Adjustments	0.00	–	0.02	–	–	–	0.00	-0.03	0.00	0.00	0.00	0.13	0.05	0.01	0.01	-0.14	-0.06	–	-0.01
Net Change in Cash	39	45	48	-5.14	-0.75	-6.67	-9.41	-10	-19	-18	-17	-23	-21	-20	-20	22	47	49	53
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	-13	-13	-14	-13	-12	-10	–	–	-3.20
Interest Paid	0.01	0.02	0.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -58.4%

Financial strength

Current ratio: 26.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2484.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.27
Dividend yield: –